# A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

Study · id `cardio:ct-nct05259033` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05259033](<https://clinicaltrials.gov/study/NCT05259033>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05259033

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 683 participants.

## Technical summary

Registry record NCT05259033. Randomized; no masking; primary purpose treatment. Start 2022-04-11 (actual); primary completion 2023-12-13 (actual). Results posted on 2025-01-17.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 683 participants (enrolled count; ClinicalTrials.gov record NCT05259033, source copy `cardio:ctgov-nct05259033-2026-06-12`, retrieved 2026-10-26)
- Started: 2022-04-11 (actual) (ClinicalTrials.gov record NCT05259033, source copy `cardio:ctgov-nct05259033-2026-06-12`, retrieved 2026-10-26)
- Primary completion: 2023-12-13 (actual) (ClinicalTrials.gov record NCT05259033, source copy `cardio:ctgov-nct05259033-2026-06-12`, retrieved 2026-10-26)
- Completion: 2024-01-16 (actual) (ClinicalTrials.gov record NCT05259033, source copy `cardio:ctgov-nct05259033-2026-06-12`, retrieved 2026-10-26)
- Results first posted: 2025-01-17 (ClinicalTrials.gov record NCT05259033, source copy `cardio:ctgov-nct05259033-2026-06-12`, retrieved 2026-10-26)
- Countries: United States; Brazil; Canada; China; France; Greece; Hungary; Israel; Japan; Russia; Slovakia; Sweden; Switzerland; Taiwan; Ukraine (ClinicalTrials.gov record NCT05259033, source copy `cardio:ctgov-nct05259033-2026-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05259033-2026-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
- Acronym: COMBINE 2
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): IcoSema
- Intervention (Drug): Semaglutide 1 mg
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial (`cardio:pubmed-39820580`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4792686b9341735842ab23e333b86ad4edfbb40e8b8f861c06cff604397bbc51
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
